Global Structural Heart Devices Market

Structural Heart Devices Market Size, Share, Growth Analysis, By Product(Heart Valve Devices (Transcatheter Heart Valves, Surgical Heart Valves (Tissue Heart Valves, Mechanical Heart Valves)), Occluders & Delivery Systems), By Procedure(Replacement Procedures (TAVR Procedures, Savr Procedures), Repair Procedures (Closure Procedures, Annuloplasty), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35G2184 | Region: Global | Published Date: October, 2024
Pages: 157 | Tables: 34 | Figures: 74

Structural Heart Devices Market Competitive Landscape

The competitive environment in the market is characterized by leading medical device manufacturers and new start-up companies specializing in advanced, simple solutions for cardiac surgery. Technological advances, increasing clinical research, and strategic partnerships focused on improving patient outcomes drive the growth of this market. Companies are actively pursuing FDA approvals and expanding their services to remain competitive. Key players are investing heavily in research and development, with a strong focus on expanding product offerings and gaining first-hand advantages in new cardiac device technologies.

Structural Heart Devices Market Top Player’s Company Profiles

  • Boston Scientific Corporation 
  • Medtronic 
  • Edwards Lifesciences Corporation 
  • Abbott Laboratories 
  • St. Jude Medical 
  • Biomerics 
  • Comed BV 
  • LivaNova PLC 
  • JenaValve Technology, Inc. 
  • CardioKinetix 
  • Lepu Medical Technology 
  • CryoLife 
  • Micro Interventional Devices 
  • Braile Biomédica 
  • TTK Healthcare (A TTK Group Company)

Structural Heart Devices Market

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Structural Heart Devices Market size was valued at USD 10.97 billion in 2022 and is poised to grow from USD 11.97 billion in 2023 to USD 24.58 billion by 2031, growing at a CAGR of 9.4% in the forecast period (2024-2031)

The competitive environment in the market is characterized by leading medical device manufacturers and new start-up companies specializing in advanced, simple solutions for cardiac surgery. Technological advances, increasing clinical research, and strategic partnerships focused on improving patient outcomes drive the growth of this market. Companies are actively pursuing FDA approvals and expanding their services to remain competitive. Key players are investing heavily in research and development, with a strong focus on expanding product offerings and gaining first-hand advantages in new cardiac device technologies. 'Boston Scientific Corporation ', 'Medtronic ', 'Edwards Lifesciences Corporation ', 'Abbott Laboratories ', 'St. Jude Medical ', 'Biomerics ', 'Comed BV ', 'LivaNova PLC ', 'JenaValve Technology, Inc. ', 'CardioKinetix ', 'Lepu Medical Technology ', 'CryoLife ', 'Micro Interventional Devices ', 'Braile Biomédica ', 'TTK Healthcare (A TTK Group Company)'

The incidence of heart failure is increasing worldwide due to factors such as aging population, sedentary lifestyle, and poor diet, leading to an increasing demand for cardiac devices, with frequent diagnosis of organized heart failure, such as aortic stenosis, mitral regurgitation, and congenital heart defects in older adults. Advanced cardiac mechanical engineering requirements are likely to perpetuate, with transcatheter intracardiac including veins and occluders. 

Increasing Adoption of Transcatheter Aortic Valve Replacement (TAVR) Systems: Transcatheter aortic valve replacement (TAVR) has become popular as the treatment of choice for patients with severe aortic stenosis, especially those unsuitable for open heart surgery. In clinical trials and ongoing safety studies with the advantages of TAVR, this less penetrating approach continues to increase the demand for structural heart devices will be expected as manufacturers are investing aggressively in next-generation TAVR systems, to expand patients to increase structural heart devices market outlook. 

North America dominated the structural heart devices industry and held the largest revenue share of 40.8% in 2022, due to rising healthcare expenditures, increasing R&D activities, and increasing incidence of heart disease due to growth so in geriatrics. The demand for minimally invasive procedures is also a major reason the region dominates. According to data released by Cedars-Sinai in January 2022, the most common heart surgery is coronary artery bypass graft surgery (CABG)/coronary artery bypass surgery Each year, more than 300,000 patients in the United States undergo surgery prominent. This explains the increasing prevalence of heart disease in the country. 

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Cardiovascular Devices Market
Buy Now GET FREE SAMPLE
Cardiac Implants Market
Buy Now GET FREE SAMPLE
Heart Pump Device Market
Buy Now GET FREE SAMPLE
Cardiac Assist Devices Market
Buy Now GET FREE SAMPLE
Interventional Cardiology Devices Market
Buy Now GET FREE SAMPLE
Cardiac Rhythm Management Devices Market
Buy Now GET FREE SAMPLE
Wearable Medical Devices Market
Buy Now GET FREE SAMPLE
Neurovascular Devices Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Structural Heart Devices Market

Report ID: SQMIG35G2184

$5,300
BUY NOW GET FREE SAMPLE